Amicogen Inc is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâ€™s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company sells its products in domestic and overseas markets.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
19/06/26	1,513.00 ₩	+15.41%	6,745,109
18/06/26	1,311.00 ₩	-0.98%	375,740
17/06/26	1,324.00 ₩	+2.00%	423,274
16/06/26	1,298.00 ₩	+0.31%	443,983
15/06/26	1,294.00 ₩	-0.77%	355,970

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 19/06/2026			5-day change	1st Jan Change
1,513.00 ^KRW	+15.41%		+16.83%	-15.10%

05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	107B 69.63M 60.71M 56.23M 52.64M 98.72M 6.57B 99.32M 667M 259M 3.23B 261M 256M 11.23B	P/E 2024	-4.02x	P/E 2025	-3.28x
Enterprise Value	194B 126M 110M 102M 95.55M 179M 11.93B 180M 1.21B 469M 5.87B 474M 464M 20.38B	EV / Sales 2024	1.86x	EV / Sales 2025	4.43x
Free-Float	95.13%	Yield 2024 *	-	Yield 2025	-

05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/09/25	Amicogen, Inc.(KOSDAQ:A092040) added to S&P Global BMI Index	CI
20/08/25	Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market	CI
14/08/25	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/08/25	Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.	CI
14/05/25	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25/04/25	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
19/03/25	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/12/24	An undisclosed buyer agreed to acquire an unknown stake in Amicogen Biopharm Co., Ltd. from Amicogen, Inc. for KRW 54.7 billion.	CI
21/11/24	Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc..	CI
14/11/24	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

20/06/24	Bio-Works and Amicogen have concluded their technology transfer project.	AQ
10/09/21	Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works	AQ
17/02/21	Bio Works Technologies : Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea	AQ

Amicogen, Inc. Stock

Stocks

A092040

KR7092040005

Biotechnology & Medical Research

Valuation: Amicogen, Inc.

Chart: Amicogen, Inc.

Latest news : Amicogen, Inc.

Press Releases: Amicogen, Inc.

News in other languages: Amicogen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Amicogen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+15.41%
1 week	+16.83%
Current month	-3.94%
1 month	-11.36%
3 months	+5.66%
6 months	-45.48%
Current year	-15.10%

1 week	1,259	1,702
1 month	1,218	1,971
Current year	1,160	2,300
1 year	1,160	4,440
3 years	1,160	9,790
5 years	1,160	23,500
10 years	1,160	24,825

Manager	Title	Age	Since
Jjeo Pyo CEO	Chief Executive Officer	53	-
Young-Chul Yoon PRN	Corporate Officer/Principal	55	28/03/2024
Chun-Gu Kim AUD	Comptroller/Controller/Auditor	69	27/03/2025

Director	Title	Age	Since
Jun-Ho Kim BRD	Director/Board Member	56	26/02/2025
Soon-Yong Kim BRD	Director/Board Member	58	26/02/2025
Young-Chul Yoon BRD	Director/Board Member	55	28/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-03	Ji-Seong So	Buy	Director	435	0.0006%
03-03	Young-Chul Yoon	Buy	Director	109	0.0002%
02-27	Eun-seong Hwang	Buy		4,000	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICOGEN, INC.	+15.41%	+16.83%	-58.09%	-84.14%	60.12M
ARGENX SE	+1.44%	-1.25%	+63.52%	+114.88%	54.44B
WUXI APPTEC CO., LTD.	+4.60%	+5.82%	+56.35%	+43.04%	45.8B
BIONTECH SE	-1.44%	+1.51%	-12.94%	-19.24%	22.98B
INSMED INCORPORATED	-2.69%	-0.95%	-3.68%	+379.00%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	+2.94%	+24.02%	-35.05%	16.25B
GENMAB A/S	+0.58%	+1.08%	+16.73%	-38.06%	15.34B
EXELIXIS, INC.	-1.01%	-2.97%	+27.42%	+171.92%	13.05B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	+5.43%	+21.37%	-	12.37B
PHARMAESSENTIA CORPORATION	+4.95%	+13.49%	+121.11%	+249.05%	12.47B
Average	+2.81%	+3.66%	+25.58%	+86.82%	21.35B
Weighted average by Cap.	+1.63%	+1.39%	+39.53%	+98.64%

	2024	2025
Net sales	174B 113M 98.88M 91.58M 85.73M 161M 10.7B 162M 1.09B 421M 5.27B 426M 417M 18.29B	41.98B 27.42M 23.91M 22.15M 20.73M 38.88M 2.59B 39.12M 263M 102M 1.27B 103M 101M 4.42B
Net income	-52.79B -34.49M -30.07M -27.85M -26.07M -48.89M -3.25B -49.19M -330M -128M -1.6B -129M -127M -5.56B	-29.96B -19.57M -17.06M -15.8M -14.79M -27.75M -1.85B -27.91M -187M -72.66M -909M -73.46M -71.89M -3.16B
Net Debt	112B 72.85M 63.52M 58.83M 55.07M 103M 6.87B 104M 698M 270M 3.38B 273M 268M 11.75B	86.91B 56.77M 49.5M 45.84M 42.92M 80.49M 5.36B 80.97M 544M 211M 2.64B 213M 209M 9.16B